moneyheap
SNY · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) stock moving?
SNY closed at $48.23 on Nov 10, up about 15% from $41.96 on Oct 22 and about 12% from the $43.13 close on Oct 29, with a series of higher highs and closes. The move began with Q3 results on Oct 30 on roughly 15.1M shares, about four times the typical daily volume of 2-5M. Business sales rose 16.2% to €14.44B, business EPS rose 22% to €3.55, and Dupixent sales rose 34.8% to €5.7B, while vaccine sales fell 6.6%. Sanofi raised its 2026 outlook to low-teens sales growth at constant exchange rates and mid-teens business EPS growth. Analysts followed with an upgrade from BNP Paribas to Outperform and from AlphaValue/Baader Europe to Add, plus target increases from UBS, RBC and AlphaValue/Baader Europe. The average 12-month target of $50.20 implies only about 4% upside from the latest close, so much of the near-term re-rating appears priced in. Risks include the discontinued STAT6 degrader SAR448272, the eventual loss of Dupixent exclusivity, which management expects to affect revenue only moderately beyond 2030, and the weaker vaccine line. Smaller items such as the Adagene equity investment, the Zus Health funding round and a UAE genomics partnership carry limited weight. Volume has normalized to about 4.6M shares while the stock sits near its 30-day high.
News behind the analysis
- Sanofi Reports Q3 2026 Financial Results and Raises Full-Year OutlookSanofi reported double-digit third-quarter 2026 sales growth and raised its full-year guidance for the second time this year.
- Sanofi Q3 Adj. EPS $2.04 Beats $1.63 Estimate, Sales $16.623B Beat $15.230B EstimateThird-quarter adjusted EPS and sales both came in above consensus estimates.
- Sanofi Raises FY26 Guidance: Sees Sales Growth Low-Teens % At CER, Business EPS Growth Mid-Teens %Sanofi raised its 2026 outlook to low-teens percent sales growth at constant exchange rates and mid-teens percent business EPS growth.
- Sanofi Q3 Dupixent Sales €5.7B, Up 34.8%; Vaccines Sales €3.2B, Down 6.6%Dupixent drove strong third-quarter growth while vaccine sales declined by 6.6%.
- Dupixent Is Still Booming. Sanofi's CEO Is Already Planning for Life Without ItManagement outlined long-term plans to handle upcoming Dupixent patent expirations alongside continued growth in the drug.
- RBC Capital Markets Raises Price Target on SanofiRBC raised its price target from EUR 75 to EUR 80 and kept a Sector Perform rating.
- Nurix Therapeutics Announces That Sanofi Notified Co. Of Its Decision To Discontinue The Phase 1 First-In-Human Clinical Trial Of SAR448272, And To Terminate The SAR448272 ProgramSanofi decided to stop the Phase 1 trial and end the SAR448272 STAT6 degrader program partnered with Nurix.
- Analysts Adjust Sanofi 12-Month Price TargetThe average 12-month analyst price target was set at $50.20, about 4% above the latest close of $48.23.
- AlphaValue/Baader Europe Upgrades Sanofi to AddAlphaValue/Baader Europe upgraded Sanofi to Add, and later raised its price target on continued Dupixent strength.
- BNP Paribas Upgrades Sanofi to OutperformBNP Paribas upgraded Sanofi from Neutral to Outperform with a $57 price target.
About Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Sanofi is a Paris-based global drugmaker that makes prescription medicines and vaccines; its US-listed ADRs (SNY) each represent half of one ordinary share. Its standout product is the immunology drug Dupixent, which it shares with Regeneron and which now brings in about 40% of sales. The company is focused on finding new growth to replace Dupixent before that drug loses patent protection.
How it makes money
Sanofi earns money by selling branded medicines and vaccines around the world. Year-to-date 2026 sales were about €36.6 billion. Dupixent alone brought in about €15 billion of that (roughly 40%), with sales coming from atopic dermatitis, asthma, COPD and other conditions. The rest comes from newer launches such as ALTUVIIIO, Ayvakit, Sarclisa and Rezurock, which make up about 15% of sales; rare-disease drugs; vaccines, including flu and Heplisav-B; and older established medicines. The US is its largest market, at roughly 60% of sales.
What usually moves SNY
- Dupixent sales growth and new approved uses
- Late-stage drug trial results and regulatory decisions
- Timing of Dupixent's future loss of patent protection
- Flu and respiratory vaccine demand
- Euro-dollar exchange rates and US drug pricing policy